Why the FDA's focus on breakthrough meds is good news

01/15/2013 | Xconomy

The pharmaceutical industry's focus will shift toward more groundbreaking, innovative medicines because of the Breakthrough Therapy Designation, the FDA's new regulatory incentive structure, Luke Timmerman writes. The emphasis on breakthrough drugs, together with the high number of drug approvals last year, is a positive development for drugmakers and patients, he writes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC